File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung
  • Basic View
  • Metadata View
  • XML View
TitleCapecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung
 
AuthorsHo, JC1
Lam, DC1
Wong, MK1
Lam, B1
Ip, MS1
Lam, WK1
 
Issue Date2009
 
PublisherLippincott Williams & Wilkins.
 
CitationJournal Of Thoracic Oncology, 2009, v. 4 n. 9, p. 1174-1177 [How to Cite?]
DOI: http://dx.doi.org/10.1097/JTO.0b013e3181b28f15
 
AbstractLymphoepithelioma-like carcinoma (LELC) of lung has previously demonstrated good clinical response to 5-fluorouracil containing chemotherapy regimen, similar to the observation in undifferentiated nasopharyngeal carcinoma. Capecitabine, which is converted into active 5-fluorouracil within tumor cells, has been found effective in colorectal, breast, and recently nasopharyngeal carcinomas. We report our experience in five patients with advanced or metastatic LELC of lung who were treated with single agent capecitabine as salvage chemotherapy. The finding of disease control in three of five patients, especially with exceptionally durable stable disease (14.8 months) in one patient, suggests the potential clinical activity of capecitabine in LELC of lung. Future studies on capecitabine-containing chemotherapy regimens in LELC of lung are warranted. © 2009 International Association for the Study of Lung Cancer.
 
DescriptionFulltext link (Free): http://journals.lww.com/jto/Fulltext/2009/09000/Capecitabine_as_Salvage_Treatment_for.19.aspx
 
ISSN1556-0864
2012 Impact Factor: 4.473
2012 SCImago Journal Rankings: 1.766
 
DOIhttp://dx.doi.org/10.1097/JTO.0b013e3181b28f15
 
ISI Accession Number IDWOS:000269495500018
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorHo, JC
 
dc.contributor.authorLam, DC
 
dc.contributor.authorWong, MK
 
dc.contributor.authorLam, B
 
dc.contributor.authorIp, MS
 
dc.contributor.authorLam, WK
 
dc.date.accessioned2010-09-06T07:35:39Z
 
dc.date.available2010-09-06T07:35:39Z
 
dc.date.issued2009
 
dc.description.abstractLymphoepithelioma-like carcinoma (LELC) of lung has previously demonstrated good clinical response to 5-fluorouracil containing chemotherapy regimen, similar to the observation in undifferentiated nasopharyngeal carcinoma. Capecitabine, which is converted into active 5-fluorouracil within tumor cells, has been found effective in colorectal, breast, and recently nasopharyngeal carcinomas. We report our experience in five patients with advanced or metastatic LELC of lung who were treated with single agent capecitabine as salvage chemotherapy. The finding of disease control in three of five patients, especially with exceptionally durable stable disease (14.8 months) in one patient, suggests the potential clinical activity of capecitabine in LELC of lung. Future studies on capecitabine-containing chemotherapy regimens in LELC of lung are warranted. © 2009 International Association for the Study of Lung Cancer.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.descriptionFulltext link (Free): http://journals.lww.com/jto/Fulltext/2009/09000/Capecitabine_as_Salvage_Treatment_for.19.aspx
 
dc.identifier.citationJournal Of Thoracic Oncology, 2009, v. 4 n. 9, p. 1174-1177 [How to Cite?]
DOI: http://dx.doi.org/10.1097/JTO.0b013e3181b28f15
 
dc.identifier.doihttp://dx.doi.org/10.1097/JTO.0b013e3181b28f15
 
dc.identifier.eissn1556-1380
 
dc.identifier.epage1177
 
dc.identifier.hkuros167339
 
dc.identifier.isiWOS:000269495500018
 
dc.identifier.issn1556-0864
2012 Impact Factor: 4.473
2012 SCImago Journal Rankings: 1.766
 
dc.identifier.issue9
 
dc.identifier.openurl
 
dc.identifier.pmid19704339
 
dc.identifier.scopuseid_2-s2.0-69549116225
 
dc.identifier.spage1174
 
dc.identifier.urihttp://hdl.handle.net/10722/77781
 
dc.identifier.volume4
 
dc.languageeng
 
dc.publisherLippincott Williams & Wilkins.
 
dc.publisher.placeUnited States
 
dc.relation.ispartofJournal of Thoracic Oncology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsJournal of Thoracic Oncology. Copyright © Lippincott Williams & Wilkins.
 
dc.subject.meshAged
 
dc.subject.meshCarcinoma, Non-Small-Cell Lung - drug therapy
 
dc.subject.meshDeoxycytidine - analogs & derivatives - therapeutic use
 
dc.subject.meshDisease Progression
 
dc.subject.meshFemale
 
dc.subject.meshFluorouracil - analogs & derivatives - therapeutic use
 
dc.subject.meshHumans
 
dc.subject.meshLung Neoplasms - drug therapy
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshSalvage Therapy
 
dc.titleCapecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Ho, JC</contributor.author>
<contributor.author>Lam, DC</contributor.author>
<contributor.author>Wong, MK</contributor.author>
<contributor.author>Lam, B</contributor.author>
<contributor.author>Ip, MS</contributor.author>
<contributor.author>Lam, WK</contributor.author>
<date.accessioned>2010-09-06T07:35:39Z</date.accessioned>
<date.available>2010-09-06T07:35:39Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>Journal Of Thoracic Oncology, 2009, v. 4 n. 9, p. 1174-1177</identifier.citation>
<identifier.issn>1556-0864</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/77781</identifier.uri>
<description>Fulltext link (Free): http://journals.lww.com/jto/Fulltext/2009/09000/Capecitabine_as_Salvage_Treatment_for.19.aspx</description>
<description.abstract>Lymphoepithelioma-like carcinoma (LELC) of lung has previously demonstrated good clinical response to 5-fluorouracil containing chemotherapy regimen, similar to the observation in undifferentiated nasopharyngeal carcinoma. Capecitabine, which is converted into active 5-fluorouracil within tumor cells, has been found effective in colorectal, breast, and recently nasopharyngeal carcinomas. We report our experience in five patients with advanced or metastatic LELC of lung who were treated with single agent capecitabine as salvage chemotherapy. The finding of disease control in three of five patients, especially with exceptionally durable stable disease (14.8 months) in one patient, suggests the potential clinical activity of capecitabine in LELC of lung. Future studies on capecitabine-containing chemotherapy regimens in LELC of lung are warranted. &#169; 2009 International Association for the Study of Lung Cancer.</description.abstract>
<language>eng</language>
<publisher>Lippincott Williams &amp; Wilkins.</publisher>
<relation.ispartof>Journal of Thoracic Oncology</relation.ispartof>
<rights>Journal of Thoracic Oncology. Copyright &#169; Lippincott Williams &amp; Wilkins.</rights>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Carcinoma, Non-Small-Cell Lung - drug therapy</subject.mesh>
<subject.mesh>Deoxycytidine - analogs &amp; derivatives - therapeutic use</subject.mesh>
<subject.mesh>Disease Progression</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Fluorouracil - analogs &amp; derivatives - therapeutic use</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Lung Neoplasms - drug therapy</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Salvage Therapy</subject.mesh>
<title>Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1556-0864&amp;volume=4&amp;issue=9&amp;spage=1174&amp;epage=1177&amp;date=2009&amp;atitle=Capecitabine+as+salvage+treatment+for+lymphoepithelioma-like+carcinoma+of+lung</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1097/JTO.0b013e3181b28f15</identifier.doi>
<identifier.pmid>19704339</identifier.pmid>
<identifier.scopus>eid_2-s2.0-69549116225</identifier.scopus>
<identifier.hkuros>167339</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-69549116225&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>4</identifier.volume>
<identifier.issue>9</identifier.issue>
<identifier.spage>1174</identifier.spage>
<identifier.epage>1177</identifier.epage>
<identifier.eissn>1556-1380</identifier.eissn>
<identifier.isi>WOS:000269495500018</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong